InterMune Reports Third Quarter 2009 Financial Results and Business ...(----- Loss from continuing op...),Health

Date:11/5/2009

----- Loss from continuing operations before income taxes (8,748) (13,654) (85,226) (72,728) Income tax expense/ (benefit) 23 325 2,217 - -- --- ----- -- Loss from continuing operations (8,771) (13,979) (87,443) (72,728) Discontinued operations: Income (loss) from discontinued operations - (3) - 71 -- -- -- -- Net loss $(8,771) $(13,982) $(87,443) $(72,657) ======= ======== ======== ======== Basic and diluted loss per share: Continuing operations $(0.19) $(0.36) $(2.00) $(1.87) Discontinued operations - - - - -- -- -- -- Net loss per share $(0.19) $(0.36) $(2.00) $(1.87) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share 45,431 39,031 43,810 38,954 ====== ====== ====== ====== * As adjusted due to the implementation of new accounting guidance in the Debt Topic of the FASB ASC, previously referred to as FSP APB 14-1 "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" InterMune, Inc. PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) September 30, December 31, 2009 2008*
'/>"/>

SOURCE InterMune, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3